Bio Tech & Pharma Disposition of International Assets for Approximately US$9.5 Million, Enabling Settlement of A$8.2 Million Debt Facility and Funding Growth of US OperationsBy Alexander LeeOctober 3, 20240 “The breadth of these data showcases our strategy to advance diverse modalities for difficult-to-treat cancers,” stated Jay Bradner, M.D., executive…
Bio Tech & Pharma Successful Divestiture of Non-US AssetsBy Alexander LeeOctober 2, 20240 At Amgen, Dr. Jay Bradner, the Executive Vice President of Research and Development and Chief Scientific Officer, emphasized the strategic…
